Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.

Endocrinology | 2015

Excessive hepatic lipid accumulation promotes macrophages/Kupffer cells activation, resulting in exacerbation of insulin resistance and progression of nonalcoholic steatohepatitis (NASH). However, few promising treatment modalities target lipotoxicity-mediated hepatic activation/polarization of macrophages for NASH. Recent epidemiological surveys showed that serum β-cryptoxanthin, an antioxidant carotenoid, was inversely associated with the risks of insulin resistance and liver dysfunction. In the present study, we first showed that β-cryptoxanthin administration ameliorated hepatic steatosis in high-fat diet-induced obese mice. Next, we investigated the preventative and therapeutic effects of β-cryptoxanthin using a lipotoxic model of NASH: mice fed a high-cholesterol and high-fat (CL) diet. After 12 weeks of CL diet feeding, β-cryptoxanthin administration attenuated insulin resistance and excessive hepatic lipid accumulation and peroxidation, with increases in M1-type macrophages/Kupffer cells and activated stellate cells, and fibrosis in CL diet-induced NASH. Comprehensive gene expression analysis showed that β-cryptoxanthin down-regulated macrophage activation signal-related genes significantly without affecting most lipid metabolism-related genes in the liver. Importantly, flow cytometry analysis revealed that, on a CL diet, β-cryptoxanthin caused a predominance of M2 over M1 macrophage populations, in addition to reducing total hepatic macrophage and T-cell contents. In parallel, β-cryptoxanthin decreased lipopolysaccharide-induced M1 marker mRNA expression in peritoneal macrophages, whereas it augmented IL-4-induced M2 marker mRNA expression, in a dose-dependent manner. Moreover, β-cryptoxanthin reversed steatosis, inflammation, and fibrosis progression in preexisting NASH in mice. In conclusion, β-cryptoxanthin prevents and reverses insulin resistance and steatohepatitis, at least in part, through an M2-dominant shift in macrophages/Kupffer cells in a lipotoxic model of NASH.

Pubmed ID: 25562616 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SAPK/JNK (56G8) Rabbit mAb (antibody)

RRID:AB_2141027

This monoclonal targets SAPK/JNK (56G8) Rabbit mAb

View all literature mentions

Muscle Actin (HUC1-1) (antibody)

RRID:AB_2223040

This monoclonal targets ACTG2

View all literature mentions

Insulin Receptor β (4B8) Rabbit mAb (antibody)

RRID:AB_2280448

This recombinant monoclonal targets Insulin Receptor beta

View all literature mentions

Phospho-SAPK/JNK (Thr183/Tyr185) (G9) Mouse mAb #9255 (antibody)

RRID:AB_2307321

This monoclonal targets synthetic phosphopeptide corresponding to residues surrounding Thr183/Tyr185 of human SAPK/JNK

View all literature mentions

Phospho-Akt (Ser473) Antibody (antibody)

RRID:AB_329825

This polyclonal targets Phospho-Akt (Ser473)

View all literature mentions

Akt Antibody (antibody)

RRID:AB_329827

This polyclonal targets Akt

View all literature mentions

NF-κB p65 Antibody (antibody)

RRID:AB_330561

This polyclonal targets NF-κB p65

View all literature mentions

Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (antibody)

RRID:AB_331284

This monoclonal targets NF-KappaB p65, phospho (Ser536)

View all literature mentions

Phospho-IGF-I Receptor beta (Tyr1131)/Insulin Receptor beta (Tyr1146) Antibody (antibody)

RRID:AB_331578

This polyclonal targets Phospho-IGF-I Receptor beta (Tyr1131)/Insulin Receptor beta (Tyr1146)

View all literature mentions

Phospho-p38 MAPK (Thr180/Tyr182) Antibody (antibody)

RRID:AB_331641

This polyclonal targets p38 MAPK, phospho (Thr180 / Tyr182)

View all literature mentions

Anti-β-Actin Antibody (antibody)

RRID:AB_476744

This monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH

View all literature mentions